Ursodiol
Brand names: Reltone, Ursodiol
At a glance
- Medicare prescriptions, 2024
- 303,379
- Medicare drug cost
- $47.4M
- Average cost per prescription
- $156
- Clinicians who prescribed it
- 10,697
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
1. Ursodiol capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established. 2.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Gastroenterology 36.7%
- Nurse Practitioners 18.0%
- Internal Medicine 11.3%
- Hepatology 10.6%
- Physician Assistants 9.1%
- Family Medicine 6.6%
- General Surgery 1.9%
- Transplant Surgery 0.9%
- Geriatric Medicine 0.9%
- Hematology & Oncology 0.7%
- Pulmonology 0.4%
- General Practice 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 18% from 2019 to 2024.
Biggest change by state since 2019
- Kentucky +31%
- Washington +31%
- Missouri +30%
- Texas +30%
- Ohio +26%
- Georgia (smallest change) +5%
- Tennessee (smallest change) +5%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Actavis Pharma, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | white capsule, 22 mm | WATSON 3159 |
Avpak
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | white capsule, 22 mm | 1483 |
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 250 mg | white capsule, 15 mm | P 412 |
Intra-Sana Laboratories
| Strength | Looks like | Imprint |
|---|---|---|
| 200 mg | white capsule, 18 mm | THICK BLACK BAR |
| 400 mg | white capsule, 22 mm | THICK BLACK BAR |
Strides Pharma Science Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | white capsule, 22 mm | UD 300 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $365,029 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Intra-sana Laboratories $365,029
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.